Announced details
Treatment of fatty liver disease and nonalcoholic steatohepatitis
Redasemtide has already been licensed to Shionogi & Co.,Ltd. The applicants for the patent are StemRIM Inc., Osaka University and Niigata University.
Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功). Business description, capital and year established: not disclosed
Application number: 2024111536. Registration (publication) number: to be determined. Validity period: not disclosed
There will be no impact on full-year financial results for the fiscal year ending July 2026. If any matter requiring disclosure arises, it will be disclosed promptly.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine drug Redasemtide (HMGB1 fragment peptide, development code: S-00515) |
| Counterparty | Shionogi & Co.,Ltd. |
| Counterparty overview | Head office: Kita-ku, Osaka; Representative Director, Chairman and CEO: Teshirogi Isao (手代木 功). Business description, capital and year established: not disclosed |
| Relationship with the Company | Redasemtide has already been licensed to Shionogi & Co.,Ltd. The applicants for the patent are StemRIM Inc., Osaka University and Niigata University. |
| Applicable area | Treatment of fatty liver disease and nonalcoholic steatohepatitis |
| Registration number and expiry date | Application number: 2024111536. Registration (publication) number: to be determined. Validity period: not disclosed |
| Impact on Business Performance | There will be no impact on full-year financial results for the fiscal year ending July 2026. If any matter requiring disclosure arises, it will be disclosed promptly. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the indications for Redasemtide, which is currently under development, and secure the possibility of developing treatments for fatty liver disease and nonalcoholic steatohepatitis in Russia.